Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeDropped

Co-Promotion of an Iron-Deficiency Anemia Treatment With Torii Pharmaceutical Co., Ltd.

First written in FY2022. 1 of 2 entries say "Dropped", first in FY2026. Latest entry: FY2026.

2entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022 – FY20262022: 120222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Termination of the Co-Promotion Agreement with Torii Pharmaceutical Co., Ltd. for an Iron-Deficiency Anemia TreatmentA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026DroppedAnnual report

    「2026年３月までに、鳥居薬品株式会社との鉄欠乏性貧血治療剤の共同販促（コ・プロモーション）権の被許諾に関する契約は終了しました。」

    鳥居薬品株式会社との鉄欠乏性貧血治療剤の共同販促契約が2026年3月までに終了したことを記載している。
  2. FY2022First statedAnnual report

    「鉄欠乏性貧血治療剤　共同販促（コ・プロモーション）権の被許諾　本件医薬品に鉄欠乏性貧血の効能が追加された後４年間」

    鳥居薬品株式会社との鉄欠乏性貧血治療剤の共同販促契約を初めて個別テーマとして記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.